VY1706

July 13, 2026: Voyager Therapeutics, Inc. (NASDAQ: VYGR) presented a late-breaking “Developing Topics” poster at AAIC 2026 (London, July 12–15) reporting six-month GLP non-human primate toxicology data for VY1706, an investigational BBB-crossing AAV gene therapy delivering a vectorized siRNA targeting MAPT mRNA/tau for Alzheimer’s disease.

Key preclinical findings: In 3- and 6-month GLP NHP studies, VY1706 was described as well tolerated with no adverse clinical pathology or histopathological findings in CNS, dorsal root ganglia, or peripheral organs (including liver) up to 5E13 vg/kg. A single IV dose achieved broad, durable, dose-dependent CNS delivery with up to 75% lowering of MAPT mRNA and tau protein in AD-relevant brain regions through six months. The company reported that ALPL mediates BBB transport, supporting potential cross-species translatability.

Regulatory/next steps: Voyager said it received FDA IND clearance for VY1706 in June 2026, enabling initiation of a clinical trial in adults with early AD, with dosing expected to begin in 2H 2026. The company previously presented three-month GLP tox data at ASGCT 2026 in May.